896-P: Demographic and Glycemic Parameters across Global Regions in Youth with T2D in Clinical Trials of Sitagliptin

• Published in: Diabetes (New York, N.Y.) Vol. 70; no. Supplement_1
• Main Authors: JALALUDIN, MUHAMMAD Y., DEEB, ASMA, ZEITLER, PHILIP, GARCIA, RAYMUNDO, NEWFIELD, RON S., SAMOILOVA, YULIA, ROSARIO, CARMEN A., SHEHADEH, NAIM, SAHA, CHANDAN K., ZHANG, YILONG, XU, ZHI JIN, SCHERER, LYNN W., ENGEL, SAMUEL S., KAUFMAN, KEITH D., SHANKAR, R. RAVI
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01.06.2021
• Subjects: Clinical trials; Diabetes; Glucose; Metformin
• ISSN: 0012-1797; 1939-327X
• DOI: 10.2337/db21-896-P

Objectives: To compare baseline characteristics of 10-17 yr old patients (pts) with T2D from different regions in clinical trials of sitagliptin as initial oral therapy (IOT, NCT01485614) or as add-on to metformin therapy (AMT, NCT01472367, NCT01760447). Methods: Demographic and baseline glycemic parameters of pts randomized in the US or Canada (NA), Latin America (LA), Europe or the Middle East (EM), or Asia Pacific (AP) were summarized by region (Table). Results: The proportion of males varied by region. While racial and ethnic distributions were generally reflective of region, the proportion of Whites in NA was higher than in other reports (e.g., ncbi.nlm.nih.gov/pmc/articles/PMC3038479). AP pts were youngest. Consistent with age, pts in AP were shorter, with lower weight and BMI across trials; however, median BMI percentile was >98% across regions and trial types. Median A1C and FPG ranged from 7.1-7.4% and 118-130.5 mg/dL (IOT) and 7.7-7.9% and 125.5-143.5 mg/dL (AMT). Despite having the lowest FPG, pts in AP (IOT) had the highest A1C. Conclusions: Despite regional differences in race, sex, and anthropometrics, pts were uniformly obese. Baseline glycemic parameters by region were generally comparable, although the younger age (all trials) and lower FPG and higher A1C (IOT) in AP pts may reflect a difference in the pathophysiology of T2D, with greater post-meal rather than fasting dysglycemia.